Sermorelin acetate is a synthetic analog of growth hormone-releasing hormone prescribed off-label under physician supervision for adult growth hormone decline, body composition support, recovery, and sleep quality. Rather than introducing exogenous growth hormone, it stimulates the pituitary to release the body's own GH through its natural feedback-regulated pathway. It is not FDA-approved for adult use. A telehealth consultation, baseline IGF-1 labs, and informed consent are required before dispensing.

Reported side effects include injection site reactions such as redness, swelling, or transient pain, facial flushing, headache, dizziness, nausea, mild peripheral edema, and transient increases in fasting glucose. Somnolence is common and consistent with the intended bedtime dosing. Contact your provider promptly if you experience significant joint pain, persistent edema, worsening glucose control, unusual headache, or visual disturbances.

Sermorelin is contraindicated in patients with active malignancy or a history of GH or IGF-1 sensitive cancers, as growth hormone and IGF-1 are mitogenic. Patients with untreated hypothyroidism, elevated baseline IGF-1, active intracranial lesions, or pituitary tumors should not use Sermorelin. It is not recommended during pregnancy or breastfeeding, and is not formulated for patients under 18 years of age.

Glucocorticoids suppress pituitary GH response and may reduce Sermorelin efficacy. Somatostatin analogs such as octreotide directly antagonize its effect and concomitant use is contraindicated. Patients on insulin or antidiabetic agents require blood glucose monitoring, as Sermorelin-stimulated GH can reduce insulin sensitivity. Patients on thyroid replacement therapy should have stable, optimized thyroid levels before and during treatment. Always disclose all current medications to your provider.

Patients with a history of cancer, diabetes, insulin resistance, hypothyroidism, or intracranial pathology should not use Sermorelin without thorough provider evaluation. GH and IGF-1 are mitogenic and can affect glucose metabolism, which may be contraindicated in certain disease states. A baseline evaluation including IGF-1, fasting glucose, HbA1c, and thyroid panel is required before prescribing.